Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Springerplus ; 1: 20, 2012.
Article in English | MEDLINE | ID: mdl-23961350

ABSTRACT

BACKGROUND: The spectrum of BRCA1/2 genetic variation in breast-ovarian cancer patients has been scarcely investigated outside Europe and North America, with few reports for South America, where Amerindian founder effects and recent multiracial immigration are predicted to result in high genetic diversity. We describe here the results of BRCA1/BRCA2 germline analysis in an Argentinean series of breast/ovarian cancer patients selected for young age at diagnosis or breast/ovarian cancer family history. METHODS: The study series (134 patients) included 37 cases diagnosed within 40 years of age and no family history (any ethnicity, fully-sequenced), and 97 cases with at least 2 affected relatives (any age), of which 57 were non-Ashkenazi (fully-sequenced) and 40 Ashkenazi (tested only for the founder mutations c.66_67delAG and c.5263insC in BRCA1 and c.5946delT in BRCA2). DISCUSSION: We found 24 deleterious mutations (BRCA1:16; BRCA2: 8) in 38/134 (28.3%) patients, of which 6/37 (16.2%) within the young age group, 15/57 (26.3%) within the non-Ahkenazi positive for family history; and 17/40 (42.5%) within the Ashkenazi. Seven pathogenetic mutations were novel, five in BRCA1: c.1502_1505delAATT, c.2626_2627delAA c.2686delA, c.2728 C > T, c.3758_3759delCT, two in BRCA2: c.7105insA, c.793 + 1delG. We also detected 72 variants of which 54 previously reported and 17 novel, 33 detected in an individual patient. Four missense variants of unknown clinical significance, identified in 5 patients, are predicted to affect protein function. While global and European variants contributed near 45% of the detected BRCA1/2 variation, the significant fraction of new variants (25/96, 26%) suggests the presence of a South American genetic component. This study, the first conducted in Argentinean patients, highlights a significant impact of novel BRCA1/2 mutations and genetic variants, which may be regarded as putatively South American, and confirms the important role of founder BRCA1 and BRCA2 mutations in Argentinean Ashkenazi Jews.

2.
Ann Hepatol ; 10(4): 452-7, 2011.
Article in English | MEDLINE | ID: mdl-21911885

ABSTRACT

BACKGROUND AND AIMS: Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-α/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia. The importance of these IL28B variants for Argentine patients remains unknown. MATERIAL AND METHODS: IL28B host genotypes (rs8099917 and rs12979860) were determined in a population of Argentine patients with European ancestry. Results were analyzed looking for their association with sustained virologic response (SVR) to PR therapy and compared with other baseline hosts' biochemical, histological and virological predictors of response. RESULTS: We studied 102 patients, 60% were men, and 40% of them were rs8099917 TT and 18% rs12979860 CC. Mean baseline serum HCV RNA was 1.673.092 IU/mL and mean F score was: 2.10 ± 1.18 (21% cirrhotic). SVR rate was higher in rs8099917 TT genotypes (55%) when compared to GT/GG (25%) (p = 0.002) and in rs1512979860 CC (64%) than in CT/TT (30%) (p = 0.004). The univariate analysis showed that rs8099917 TT (OR 3.7; 95 %CI 1.5-8.7; p = 0.002), rs12979860 CC (OR 4.6; 95%CI 1.5-13.7; p = 0.006), low viral load (OR 4.6; 95% CI 1.7-12.6; p = 0.002) and F0-2 (OR 8.5; 95% CI 2.3-30.6; p = 0.001) were significantly associated with SVR. In the multivariate analysis, rs12979860 CC, rs8099917 TT, viral load < 400.000 IU/mL and F0-2 were associated with SVR rates (p = 0.029, p = 0.012, p = 0.013 and p = 0.004, respectively). CONCLUSION: IL28B host genotypes should be added to baseline predictors of response to PR therapy in Latin American patients with European ancestry.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Interleukins/genetics , Polyethylene Glycols/therapeutic use , Polymorphism, Single Nucleotide , Ribavirin/therapeutic use , Adult , Argentina/epidemiology , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Hepatitis C/diagnosis , Hepatitis C/ethnology , Hepatitis C/genetics , Hepatitis C/immunology , Humans , Interferon alpha-2 , Interferons , Logistic Models , Male , Middle Aged , Odds Ratio , Phenotype , RNA, Viral/blood , Recombinant Proteins/therapeutic use , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Viral Load , White People/genetics
3.
J Clin Endocrinol Metab ; 92(5): 1891-6, 2007 May.
Article in English | MEDLINE | ID: mdl-17244780

ABSTRACT

CONTEXT: An association between germline aryl hydrocarbon receptor-interacting protein (AIP) gene mutations and pituitary adenomas was recently shown. OBJECTIVE: The objective of the study was to assess the frequency of AIP gene mutations in a large cohort of patients with familial isolated pituitary adenoma (FIPA). DESIGN: This was a multicenter, international, collaborative study. SETTING: The study was conducted in 34 university endocrinology and genetics departments in nine countries. PATIENTS: Affected members from each FIPA family were studied. Relatives of patients with AIP mutations underwent AIP sequence analysis. MAIN OUTCOME MEASURES: Presence/absence and description of AIP gene mutations were the main outcome measures. INTERVENTION: There was no intervention. RESULTS: Seventy-three FIPA families were identified, with 156 patients with pituitary adenomas; the FIPA cohort was evenly divided between families with homogeneous and heterogeneous tumor expression. Eleven FIPA families had 10 germline AIP mutations. Nine mutations, R16H, G47_R54del, Q142X, E174frameshift, Q217X, Q239X, K241E, R271W, and Q285frameshift, have not been described previously. Tumors were significantly larger (P = 0.0005) and diagnosed at a younger age (P = 0.0006) in AIP mutation-positive vs. mutation-negative subjects. Somatotropinomas predominated among FIPA families with AIP mutations, but mixed GH/prolactin-secreting tumors, prolactinomas, and nonsecreting adenomas were also noted. Approximately 85% of the FIPA cohort and 50% of those with familial somatotropinomas were negative for AIP mutations. CONCLUSIONS: AIP mutations, of which nine new mutations have been described here, occur in approximately 15% of FIPA families. Although pituitary tumors occurring in association with AIP mutations are predominantly somatotropinomas, other tumor types are also seen. Further study of the impact of AIP mutations on protein expression and activity is necessary to elucidate their role in pituitary tumorigenesis in FIPA.


Subject(s)
Adenoma/genetics , Pituitary Neoplasms/genetics , Proteins/genetics , Adenoma/pathology , Adult , Aged , Cohort Studies , Female , Gene Frequency , Germ-Line Mutation/genetics , Growth Hormone/metabolism , Humans , Immunohistochemistry , Intracellular Signaling Peptides and Proteins , Male , Middle Aged , Molecular Sequence Data , Mutation/physiology , Pituitary Neoplasms/pathology , Prolactinoma/genetics , Prolactinoma/metabolism , Prolactinoma/pathology
4.
Clin Dev Immunol ; 11(3-4): 253-9, 2004.
Article in English | MEDLINE | ID: mdl-15559371

ABSTRACT

Several different cytokines trigger the development of determined cell subsets in BALT of growing Wistar rats. Early appearance (4 days post partum) of gammadeltaT cells in BALT has been shown, as well as its role in up-regulating TNF-alpha production. In the present report, we studied in the BALT: (1) the profile of the cytokines, TNF-alpha, INF-alpha and IL-10 and (2) in TCR gammadelta+ cells, the existence of a colocalization with TNF-alpha as well as with INF-gamma. All the cytokines studied were observed at an early stage of BALT development by immunohistochemistry and in bronchoalveolar cells (BAL cells) by flow cytometry and western blot. (1) The principal cytokine found at 4 days of age in BALT cells was TNF-alpha that increases along BALT development. The same behavior was found for cells containing IL-10 and INF-gamma. (2) TCR gammadelta+ cells colocalize mainly with TNF-alpha as it has been shown by immunohistochemistry in BALT and by flow cytometry when we studied BAL. The early appearance of TNF-alpha concomitant with TCR gammadelta+ cell suggests an important role for this cytokine along BALT development. Moreover, mutual regulation between them exists taking part in the immune surveillance and repair of damaged epithelia.


Subject(s)
Bronchi/immunology , Cytokines/biosynthesis , Lymphoid Tissue/immunology , Tumor Necrosis Factor-alpha/biosynthesis , Animals , Bronchi/cytology , Bronchoalveolar Lavage Fluid/cytology , Bronchoalveolar Lavage Fluid/immunology , Female , Interferon-gamma/biosynthesis , Interleukin-10/biosynthesis , Lymphoid Tissue/cytology , Lymphoid Tissue/growth & development , Male , Rats , Rats, Wistar , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocyte Subsets/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...